Lupin Pharmaceuticals, Inc. secured FDA approval for generic Escitalopram Oxalate oral tablets, expanding its portfolio in the widely utilized antidepressant market. This regulatory clearance is expected to intensify competition within the segment, positioning Lupin to potentially capture increased market share and drive revenue growth.